Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
度伐利尤单抗联合或不联合贝伐珠单抗治疗肝细胞癌经动脉化疗栓塞术（EMERALD-1）：一项多区域、随机、双盲、安慰剂对照的3期研究
期刊:Lancet
影响因子:88.5
doi:10.1016/S0140-6736(24)02551-0
Sangro, Bruno; Kudo, Masatoshi; Erinjeri, Joseph P; Qin, Shukui; Ren, Zhenggang; Chan, Stephen L; Arai, Yasuaki; Heo, Jeong; Mai, Anh; Escobar, Jose; Lopez Chuken, Yamil Alonso; Yoon, Jung-Hwan; Tak, Won Young; Breder, Valeriy V; Suttichaimongkol, Tanita; Bouattour, Mohamed; Lin, Shi-Ming; Peron, Jean-Marie; Nguyen, Quang T; Yan, Lunan; Chiu, Chang-Fang; Santos, Florinda A; Veluvolu, Anil; Thungappa, Satheesh Chiradoni; Matos, Marco; Żotkiewicz, Magdalena; Udoye, Stephanie I; Kurland, John F; Cohen, Gordon J; Lencioni, Riccardo
